These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 18398600

  • 1. Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.
    Someya Y, Tahara A, Nakano R, Matsuyama-Yokono A, Nagase I, Fukunaga Y, Takasu T, Hayakawa M, Shibasaki M.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 May; 377(3):209-17. PubMed ID: 18398600
    [Abstract] [Full Text] [Related]

  • 2. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.
    Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M.
    Pharmacol Rep; 2009 May; 61(5):899-908. PubMed ID: 19904014
    [Abstract] [Full Text] [Related]

  • 3. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity.
    Matsuyama-Yokono A, Tahara A, Nakano R, Someya Y, Nagase I, Hayakawa M, Shibasaki M.
    Biochem Pharmacol; 2008 Jul 01; 76(1):98-107. PubMed ID: 18468582
    [Abstract] [Full Text] [Related]

  • 4. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
    Yamazaki K, Yasuda N, Inoue T, Nagakura T, Kira K, Shinoda M, Saeki T, Tanaka I.
    J Pharmacol Exp Ther; 2006 Dec 01; 319(3):1253-7. PubMed ID: 16980568
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M.
    Pharmacology; 2009 Dec 01; 83(3):177-87. PubMed ID: 19176982
    [Abstract] [Full Text] [Related]

  • 6. Effects of the dipeptidyl peptidase-IV inhibitor ASP8497 on glucose tolerance in animal models of secondary failure.
    Someya Y, Nakano R, Tahara A, Takasu T, Takeuchi A, Nagase I, Matsuyama-Yokono A, Hayakawa M, Sasamata M, Miyata K, Uchiyama Y.
    Eur J Pharmacol; 2009 Nov 10; 622(1-3):71-7. PubMed ID: 19766107
    [Abstract] [Full Text] [Related]

  • 7. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A, Yamamoto K, Kozakai A, Okumura-Kitajima L, Mita Y, Kitano K, Jingu S, Nakaike S.
    Eur J Pharmacol; 2011 Mar 25; 655(1-3):99-107. PubMed ID: 21262219
    [Abstract] [Full Text] [Related]

  • 8. Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M.
    Eur J Pharmacol; 2009 Mar 01; 605(1-3):170-6. PubMed ID: 19171131
    [Abstract] [Full Text] [Related]

  • 9. E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor.
    Yasuda N, Nagakura T, Inoue T, Yamazaki K, Katsutani N, Takenaka O, Clark R, Matsuura F, Emori E, Yoshikawa S, Kira K, Ikuta H, Okada T, Saeki T, Asano O, Tanaka I.
    Eur J Pharmacol; 2006 Oct 24; 548(1-3):181-7. PubMed ID: 16973152
    [Abstract] [Full Text] [Related]

  • 10. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Matsuyama-Yokono A, Tahara A, Nakano R, Someya Y, Shiraki K, Hayakawa M, Shibasaki M.
    Metabolism; 2009 Mar 24; 58(3):379-86. PubMed ID: 19217455
    [Abstract] [Full Text] [Related]

  • 11. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
    Kim KR, Rhee SD, Kim HY, Jung WH, Yang SD, Kim SS, Ahn JH, Cheon HG.
    Eur J Pharmacol; 2005 Jul 25; 518(1):63-70. PubMed ID: 16106524
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
    Lee B, Shi L, Kassel DB, Asakawa T, Takeuchi K, Christopher RJ.
    Eur J Pharmacol; 2008 Jul 28; 589(1-3):306-14. PubMed ID: 18538760
    [Abstract] [Full Text] [Related]

  • 13. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S, Roy S, Sethi S, Benjamin B, Sundaram S, Khanna V, Kandalkar SR, Pal C, Kant R, Patra AK, Rayasam G, Mittra S, Saini KS, Paliwal J, Chugh A, Ahmed S, Sattigeri J, Cliff I, Ray A, Bansal VS, Bhatnagar PK, Davis JA.
    Eur J Pharmacol; 2011 Feb 10; 652(1-3):157-63. PubMed ID: 20540938
    [Abstract] [Full Text] [Related]

  • 14. ASP4,000, a novel, selective, dipeptidyl peptidase 4 inhibitor with antihyperglycemic activity.
    Tanaka-Amino K, Matsumoto K, Hatakeyama Y, Shima I, Takakura S, Muto S.
    Eur J Pharmacol; 2008 Aug 20; 590(1-3):444-9. PubMed ID: 18582861
    [Abstract] [Full Text] [Related]

  • 15. Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice.
    Matsuyama-Yokono A, Tahara A, Nakano R, Someya Y, Hayakawa M, Shibasaki M.
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Feb 20; 379(2):191-9. PubMed ID: 18762913
    [Abstract] [Full Text] [Related]

  • 16. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.
    Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, Aubert ML.
    Diabetes; 2002 May 20; 51(5):1461-9. PubMed ID: 11978643
    [Abstract] [Full Text] [Related]

  • 17. Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model.
    Davis JA, Kumar PS, Singh S, Surender A, Roy S, Khanna V, Sethi S, Pal C, Sharma L, Benjamin B, Mittra S, Sattigeri J, Bansal VS.
    Indian J Pharmacol; 2012 May 20; 44(6):759-64. PubMed ID: 23248408
    [Abstract] [Full Text] [Related]

  • 18. 2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
    Tsu H, Chen X, Chen CT, Lee SJ, Chang CN, Kao KH, Coumar MS, Yeh YT, Chien CH, Wang HS, Lin KT, Chang YY, Wu SH, Chen YS, Lu IL, Wu SY, Tsai TY, Chen WC, Hsieh HP, Chao YS, Jiaang WT.
    J Med Chem; 2006 Jan 12; 49(1):373-80. PubMed ID: 16392822
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor.
    Jain MR, Joharapurkar AA, Bahekar RH, Patel H, Jadav P, Kshirsagar SG, Patel VJ, Patel KN, Ramanathan VK, Patel PR, Desai RC.
    J Diabetes; 2015 Sep 12; 7(5):708-17. PubMed ID: 25327540
    [Abstract] [Full Text] [Related]

  • 20. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.
    Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, Chan CC, Edmondson S, Feeney WP, He H, Ippolito DE, Kim D, Lyons KA, Ok HO, Patel RA, Petrov AN, Pryor KA, Qian X, Reigle L, Woods A, Wu JK, Zaller D, Zhang X, Zhu L, Weber AE, Thornberry NA.
    Diabetes; 2005 Oct 12; 54(10):2988-94. PubMed ID: 16186403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.